Comparison of Chitodex Gel vs NexFoam on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis

Sponsor
St. Louis University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05083741
Collaborator
(none)
30
1
7.1
4.2

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the efficacy and outcomes of Chitodex gel plus Kenalog versus Nexfoam plus Kenalog in patients with chronic rhinosinusitis (CRS) undergoing sinus surgery. Both dressings are already known to be beneficial in controlling postoperative bleeding and promote wound healing.

Condition or Disease Intervention/Treatment Phase
  • Device: Chitogel
  • Device: Nexfoam

Detailed Description

The trial will be single blinded randomized controlled trial and patients recruited will undergo endoscopic sinus surgery as standard of care for treatment of CRS. Specific outcome measures will be objective and subjective outcome scores post surgery.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Head to Head Comparison of Chitodex Gel With Triamcinolone vs NexFoam With Triamcinalone on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis (CRS)
Actual Study Start Date :
Dec 27, 2021
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Chitogel

Chitodex gel plus Kenalog inserted into the middle meatus

Device: Chitogel
post-operative dressing within standard of care

Nexfoam

NexFoam plus Kenalog inserted into the middle meatus

Device: Nexfoam
post-operative dressing within standard of care

Outcome Measures

Primary Outcome Measures

  1. Clinical Scores on Endoscopy [12 (±2) weeks post surgery]

    Outcome measured based on the wound healing in the sinus openings made during surgery.

Secondary Outcome Measures

  1. Symptom Scores on Patients' Self-Directed Questionnaires [12 (±2) weeks post surgery]

    Outcomes measured based on patients' personal symptom assessment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Those who have had symptoms of chronic rhinosinusitis (nasal discharge, postnasal drip, nasal obstruction, facial pain and pressure, lack of sense of smell) that has been previously persistent for greater than 3 months AND

  2. ≥ 18 years to ≤ 90 years AND

  3. English speaking AND

  4. Able to give written informed consent AND

  5. Local residents who will be returning to this center for postoperative follow-up care AND

  6. Indicated to undergo endoscopic sinus surgery and willing to return at 2-4, 6-8 & 12 (± 2) weeks post-op.

Exclusion Criteria:
  1. allergy to shellfish

  2. pregnant or breastfeeding

  3. Hepatitis or blood disorders

  4. any drug allergy

  5. allergy to potato starch (due to Nexfoam)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Saint Louis University Saint Louis Missouri United States 63104

Sponsors and Collaborators

  • St. Louis University

Investigators

  • Principal Investigator: Joseph D Brunworth, MD, Department of Otolaryngology-Head & Neck Surgery

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Joseph Brunworth, MD, Assistant Professor, St. Louis University
ClinicalTrials.gov Identifier:
NCT05083741
Other Study ID Numbers:
  • 31454
First Posted:
Oct 19, 2021
Last Update Posted:
Jan 28, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 28, 2022